<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02435186</url>
  </required_header>
  <id_info>
    <org_study_id>rAd-p53-H20150111</org_study_id>
    <nct_id>NCT02435186</nct_id>
  </id_info>
  <brief_title>p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer</brief_title>
  <official_title>Recombinant Adenoviral p53 Human Gene Combined With Chemotherapy in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen SiBiono GeneTech Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenzhen SiBiono GeneTech Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study objective is to investigate the efficacy and safety of p53 combined with
      chemotherapy (cisplatin and paclitaxel) in treatment of recurrent Ovarian Epithelial Cancer,
      Fallopian Tube Cancer, and Primary Peritoneal Cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study objective is to investigate the efficacy and safety of p53 combined with
      chemotherapy (cisplatin and paclitaxel) in treatment of recurrent Ovarian Epithelial Cancer,
      Fallopian Tube Cancer, and Primary Peritoneal Cancer.

      study design: open-labeled, active controlled, randomized, phase 2 treatments: experiment
      group will consist of intraperitoneal p53 (2 x 10^12 viral particles) plus cisplatin 150
      mg/m^2, and Paclitaxel 175 mg/m^2 IV over 3 h on day 1; every 21 d for 6 cycles.

      study end points: response rate, progression-free survival, overall survival and Karnofsky
      score（KPS).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>response rate</measure>
    <time_frame>from starting study treatment to 6 months</time_frame>
    <description>Objective response rate using RECIST version 1.1 guidance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>progress-free survival</measure>
    <time_frame>from starting treatment to 2 years after</time_frame>
    <description>measure the time to progression/death, or to the last tumor assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>from starting study treatment to 2 years after</time_frame>
    <description>measure the time to death, or time last known alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Karnofsky Performance Status score（KPS）</measure>
    <time_frame>from starting study treatment to 2 years after</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety as measured by adverse events, vital signs, clinical lab tests, ECG and physical examination</measure>
    <time_frame>from starting study treatment to 30 days after the last study treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Ovarian Epithelial Cancer</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Primary Peritoneal Cancer</condition>
  <arm_group>
    <arm_group_label>p53 gene plus chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intraperitoneal p53 gene plus cisplatin, and paclitaxel iv</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intraperitoneal cisplatin, and paclitaxel iv</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>p53 gene</intervention_name>
    <description>p53 gene will be given intraperitoneally.</description>
    <arm_group_label>p53 gene plus chemotherapy</arm_group_label>
    <other_name>recombinant adenoviral human p53 gene</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>150 mg/m^2 cisplatin will be given intraperitoneally.</description>
    <arm_group_label>p53 gene plus chemotherapy</arm_group_label>
    <arm_group_label>chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel (175 mg/m2, 3 h) will be given by iv</description>
    <arm_group_label>p53 gene plus chemotherapy</arm_group_label>
    <arm_group_label>chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. histopathologically diagnosed ovarian epithelial cancer, fallopian tube cancer, and
             primary peritoneal cancer

          2. recurrent

          3. 18 years or older

          4. with normal tests of hemogram, blood coagulation, liver and kidney function

          5. signed the informed consent form.

        Exclusion Criteria:

          1. Serious blood coagulation disorder, bleeding tendency, platelet &lt; 6 * 1000000000/L;

          2. have serious heart, lung function abnormalities or severe diabetes patients;

          3. active infection;

          4. severe atherosclerosis;

          5. AIDS patients;

          6. serious thrombotic or embolic events within 6 months;

          7. renal insufficiency requiring hemodialysis or peritoneal dialysis;

          8. pregnant or lactating women;

          9. mental disorder or disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>xiuqing Li, MD</last_name>
    <phone>+86 18940251286</phone>
    <email>2403621353@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>qing yu, MD</last_name>
    <phone>+8618620099810</phone>
    <email>qingyu1110@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>xijing hospital in China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>xiuqing Li, MD</last_name>
      <phone>+86 18940251286</phone>
      <email>2403621353@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2015</study_first_submitted>
  <study_first_submitted_qc>April 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2015</study_first_posted>
  <last_update_submitted>April 30, 2015</last_update_submitted>
  <last_update_submitted_qc>April 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>p53 gene</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>recurrent</keyword>
  <keyword>epithelial</keyword>
  <keyword>ovarian cancer</keyword>
  <keyword>fallopian tube cancer</keyword>
  <keyword>primary peritoneal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

